Basilea Pharmaceutica AG (BSLN.SW)
CHF 41.65
(0.24%)
CHF 41.65
(0.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 116.11 Million CHF | -22.88% |
| 2022 | 150.57 Million CHF | -8.19% |
| 2021 | 164 Million CHF | -12.16% |
| 2020 | 186.7 Million CHF | 30.37% |
| 2019 | 143.22 Million CHF | 498.05% |
| 2018 | 23.94 Million CHF | 632.18% |
| 2017 | -4.5 Million CHF | 89.78% |
| 2016 | -44.03 Million CHF | 62.71% |
| 2015 | -118.06 Million CHF | 24.38% |
| 2014 | -156.12 Million CHF | -31.31% |
| 2013 | -118.89 Million CHF | 46.51% |
| 2012 | -222.29 Million CHF | -29.13% |
| 2011 | -172.14 Million CHF | -29.44% |
| 2010 | -132.98 Million CHF | -17.3% |
| 2009 | -113.37 Million CHF | -44.19% |
| 2008 | -78.63 Million CHF | 53.7% |
| 2007 | -169.81 Million CHF | -364.07% |
| 2006 | -36.59 Million CHF | -23.48% |
| 2005 | -29.63 Million CHF | 47.58% |
| 2004 | -56.53 Million CHF | 10.81% |
| 2003 | -63.38 Million CHF | -109.87% |
| 2002 | -30.2 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 32.72 Million CHF | 0.0% |
| 2023 Q4 | 116.11 Million CHF | 0.0% |
| 2023 Q2 | 78.82 Million CHF | 0.0% |
| 2023 FY | 116.11 Million CHF | -22.88% |
| 2022 FY | 150.57 Million CHF | -8.19% |
| 2022 Q4 | 150.57 Million CHF | 0.0% |
| 2022 Q2 | 184.44 Million CHF | 0.0% |
| 2021 FY | 164 Million CHF | -12.16% |
| 2021 Q2 | 144.97 Million CHF | 0.0% |
| 2021 Q4 | 164 Million CHF | 0.0% |
| 2020 Q4 | 186.7 Million CHF | 0.0% |
| 2020 Q2 | 138.27 Million CHF | 0.0% |
| 2020 FY | 186.7 Million CHF | 30.37% |
| 2019 Q2 | 69 Million CHF | 0.0% |
| 2019 FY | 143.22 Million CHF | 498.05% |
| 2019 Q4 | 143.22 Million CHF | 0.0% |
| 2018 FY | 23.94 Million CHF | 632.18% |
| 2018 Q4 | 23.94 Million CHF | 0.0% |
| 2018 Q2 | 59.31 Million CHF | 0.0% |
| 2017 Q4 | -4.5 Million CHF | 0.0% |
| 2017 Q2 | 52.74 Million CHF | 0.0% |
| 2017 FY | -4.5 Million CHF | 89.78% |
| 2016 Q4 | -43.56 Million CHF | 0.0% |
| 2016 Q2 | -65.83 Million CHF | 0.0% |
| 2016 FY | -44.03 Million CHF | 62.71% |
| 2015 Q2 | -136.88 Million CHF | 0.0% |
| 2015 Q4 | -118.35 Million CHF | 0.0% |
| 2015 FY | -118.06 Million CHF | 24.38% |
| 2014 FY | -156.12 Million CHF | -31.31% |
| 2014 Q4 | -156.12 Million CHF | 0.0% |
| 2014 Q2 | -130.88 Million CHF | 0.0% |
| 2013 Q2 | -142.75 Million CHF | 0.0% |
| 2013 FY | -118.89 Million CHF | 46.51% |
| 2013 Q4 | -118.89 Million CHF | 0.0% |
| 2012 Q2 | -69.03 Million CHF | 0.0% |
| 2012 FY | -222.29 Million CHF | -29.13% |
| 2012 Q4 | -222.29 Million CHF | 0.0% |
| 2011 FY | -172.14 Million CHF | -29.44% |
| 2011 Q2 | -93.28 Million CHF | 0.0% |
| 2011 Q4 | -172.14 Million CHF | 0.0% |
| 2010 Q2 | -93.82 Million CHF | 0.0% |
| 2010 FY | -132.98 Million CHF | -17.3% |
| 2010 Q4 | -132.98 Million CHF | 0.0% |
| 2009 Q4 | -113.37 Million CHF | 0.0% |
| 2009 FY | -113.37 Million CHF | -44.19% |
| 2008 FY | -78.63 Million CHF | 53.7% |
| 2007 FY | -169.81 Million CHF | -364.07% |
| 2006 FY | -36.59 Million CHF | -23.48% |
| 2005 FY | -29.63 Million CHF | 47.58% |
| 2004 FY | -56.53 Million CHF | 10.81% |
| 2003 FY | -63.38 Million CHF | -109.87% |
| 2002 FY | -30.2 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Addex Therapeutics Ltd | -3.52 Million CHF | 3397.706% |
| BB Biotech AG | 304.39 Million CHF | 61.854% |
| Evolva Holding SA | -5.83 Million CHF | 2088.747% |
| Idorsia Ltd | 1.05 Billion CHF | 89.031% |
| Kuros Biosciences AG | -8.69 Million CHF | 1436.214% |
| Molecular Partners AG | -183.23 Million CHF | 163.37% |
| Relief Therapeutics Holding AG | -10.24 Million CHF | 1233.402% |
| Santhera Pharmaceuticals Holding AG | -5.3 Million CHF | 2287.585% |